Skip to main content
Premium Trial:

Request an Annual Quote

IP Update: Recent Patents, Patent Applications Awarded to Alnylam, Medtronic, Cerulean, and More


Title: miRNA Triplex Formations for the Down-Regulation of Viral Replication

Patent Number: 8,323,891

Filed: July 30, 2009

Inventor: Omar Bagasra, Claflin University

“Using miRNAs having high homology with both HIV-1 and a co-infecting virus such as HHV-6, HHV-7, or GVB-C, one can inhibit viral replication, more particularly HIV-1 replication using such mutually homologous miRNAs that give rise to the creation of stable triplex formations effective in the down-regulation and/or inhibition of viral replication,” the patent's abstract states.

Title: Administration of Exogenous miRNA or siRNA

Patent Number: 8,323,893

Filed: Oct. 19, 2010

Lead Inventor: Christina Leslie, Sloan-Kettering Institute for Cancer Research

“Certain genes controlled by endogenous miRNA are actually up-regulated upon the transfection of exogenous mi/siRNA,” the patent's abstract states. “Based on this, methods of determining whether administration of mi/siRNA will have a deleterious effect by up-regulating certain genes are provided. Comparison of sequences of exogenous mi/siRNA allows selection of exogenous miRNA to be administered to cell to enhance or limit this affect, and therefore to control unwanted dysregulation or to up-regulate an endogenous miRNA-regulated gene of interest.”

Title: Modulation of Gene Expression by Oligomers Targeted to Chromosomal DNA

Patent Number: 8,324,181

Filed: March 30, 2010

Lead Inventor: David Corey, University of Texas

“Synthesis of a target transcript of a gene is selectively increased in a mammalian cell by contacting the cell with a polynucleotide oligomer of 12-28 bases complementary to a region within a target promoter of the gene under conditions whereby the oligomer selectively increases synthesis of the target transcript,” according to the patent's abstract.

Title: microRNA Associated with Rheumatoid Arthritis

Patent Number: 8,324,183

Filed: Nov. 28, 2011

Lead Inventor: Seiji Kawano, Kobe University

The patent, its abstract states, claims a microRNA, including miR-124a, whose expression is specifically increased or decreased in rheumatoid arthritis. The patent also claims a therapeutic agent for rheumatoid arthritis that includes the miRNA.

Title: Compositions and Methods for Delivering RNAi Using Lipoproteins

Patent Number: 8,324,366

Filed: April 29, 2009

Lead Inventor: Akin Akinc, Alnylam Pharmaceuticals

“This invention relates to new compositions comprising at least one of a single- or double-stranded oligonucleotide, where said oligonucleotide has been conjugated to a lipophile and to which the conjugated oligonucleotide has been preassembled with lipoproteins,” the patent's abstract states. “These compositions are effective in delivering oligonucleotides to mammalian tissue where they effect gene silencing.”

Title: Compositions and Methods for Making Therapies Delivered by Viral Vectors Reversible for Safety and Allele-Specificity

Patent Number: 8,324,367

Filed: Oct. 19, 2009

Lead Inventor: William Kaemmerer, Medtronic

The invention, the patent's abstract states, “is directed to compositions, methods, and kits for regulation of gene therapies for Huntington's disease, including, without limitation, reversible gene therapies and allele-specific therapies.”

Title: Interfering RNA Molecules

Patent Number: 8,324,370

Filed: Jan. 7, 2011

Lead Inventor: Klaus Giese, Silence Therapeutics

The invention, the patent's abstract states, relates to a blunt-ended double-stranded RNA in which the first strand “comprises a ... stretch of contiguous nucleotides ... at least partially complementary to a target nucleic acid, and the second strand comprises a ... stretch of contiguous nucleotides ... at least partially identical to a target nucleic acid.”

Title: RNA Interference Target for Treating AIDS

Application Number: 20120301449

Filed: Aug. 13, 2012

Lead Inventor: Tong Cheng, Xiamen University

The invention, the patent application's abstract states, relates to “RNAi target sequences, which could be used for treating AIDS through targeting HIV. Based on the target sequences, recombinant expression vectors, packaging vectors, and cells were constructed [to] express [an] siRNA … miRNA … ribozyme, and/or antisense oligonucleotide for targeting HIV.” The application also claims the use of these recombinant expression vectors, packaging vectors, and cells in preparing a treatment for AIDS.

Title: Liposome Containing shRNA Molecule Targeting a Thymidylate Synthase and Use Thereof

Application Number: 20120301537

Filed: Oct. 14, 2011

Lead Inventor: Tatsuhiro Ishida, Delta-Fly Pharma

The invention comprises a method for “delivering shRNA targeting [thymidylate synthase] in vivo,” the patent application's abstract states. Also provided is “an anti-tumor agent [composed of] short hairpin RNA capable of inhibiting expression of thymidylate synthase by RNAi … and a PEG-modified cationic liposome, wherein the shRNA is bound to the surface of the PEG-modified cationic liposome and has an overhang comprising at least two nucleotides at the 3' end.”

Title: Method to Quantify siRNAs, miRNAs, and Polymorphic miRNAs

Application Number: 20120301876

Filed: April 26, 2012

Lead Inventor: Ruoying Tan, Life Technologies

The invention, the patent application's abstract states, claims “methods, compositions, and kits for quantifying target polynucleotides. In some embodiments, a reverse stem-loop ligation probe is ligated to the 3' end of a target polynucleotide, using a ligase that can ligate the 3' end of RNA to the 5' end of DNA using a DNA template, such as T4 DNA ligase. Following digestion to form an elongated target polynucleotide with a liberated end, a reverse transcription reaction can be performed, followed by a PCR. In some embodiments, the methods of the [invention] can discriminate between polymorphic polynucleotides that vary by as little as one nucleotide.”

Title: Conjugates, Particles, Compositions, and Related Methods

Application Number: 20120302622

Filed: April 10, 2012

Lead Inventor: Scott Eliasof, Cerulean Pharma

The invention comprises “particles and conjugates for delivering nucleic acid agents,” the patent application's abstract states. Also claimed are “compositions containing the particles, the conjugates, or both … [as well as] methods of using the particles, the conjugates, and the compositions.”

The Scan

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.

EHR Quality Improvement Study Detects Demographic-Related Deficiencies in Cancer Family History Data

In a retrospective analysis in JAMA Network Open, researchers find that sex, ethnicity, language, and other features coincide with the quality of cancer family history information in a patient's record.

Inflammatory Bowel Disease Linked to Gut Microbiome Community Structure Gradient in Meta-Analysis

Bringing together data from prior studies, researchers in Genome Biology track down microbial taxa and a population structure gradient with ties to ulcerative colitis or Crohn's disease.

Ancient Greek Army Ancestry Highlights Mercenary Role in Historical Migrations

By profiling genomic patterns in 5th century samples from in and around Himera, researchers saw diverse ancestry in Greek army representatives in the region, as they report in PNAS.